Scarica l'app Stockscreener
1.78
0.00%
0.00
Dopo l'orario di chiusura:
1.75
-0.03
-1.69%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché HRTX Giù?
Forum
Previsione
Frazionamento azionario
Heron Therapeutics Inc Borsa (HRTX) Ultime notizie
Heron Therapeutics Announces Appointment of Michael Kaseta to Board of Directors - StockTitan
Bunion Market Forecasted to Surge in Coming Years, 2024-2034 Analysis by DelveInsight | Heron Therapeutics, Lotus Clinical Research, Cali Pharma, Grünenthal GmbH, Pacira Pharma, Inc, Mallinckrodt - The Globe and Mail
Heron Therapeutics to Report Third Quarter 2024 Financial Results On Tuesday, November 12, 2024 - Longview News-Journal
SG Americas Securities LLC Cuts Stake in Heron Therapeutics, Inc. (NASDAQ:HRTX) - Defense World
Antinauseants Market Insights, Forecast to 2031Heron - openPR
The Manufacturers Life Insurance Company Acquires 6,328 Shares of Heron Therapeutics, Inc. (NASDAQ:HRTX) - Defense World
Heron Therapeutics, Inc. (NASDAQ:HRTX) Short Interest Update - MarketBeat
Heron Therapeutics Inc (HRTX) deserves deeper analysis - US Post News
Investor’s Toolkit: Key Ratios for Assessing Heron Therapeutics Inc (HRTX)’s Performance - The Dwinnex
Heron Therapeutics, Inc. (NASDAQ:HRTX) Shares Sold by Millennium Management LLC - Defense World
Heron Therapeutics, Inc. (NASDAQ:HRTX) Shares Bought by Congress Park Capital LLC - MarketBeat
Heron Therapeutics Reaffirms Availability and Ample Supply of CINVANTI®, SUSTOL®, and APONVIE® as Alternatives During the Potential Shortage of Intravenous Fluids - The Malaysian Reserve
Its Stock Has Paid Off Big Time For Heron Therapeutics Inc - SETE News
AQR Capital Management LLC Raises Holdings in Heron Therapeutics, Inc. (NASDAQ:HRTX) - MarketBeat
Heron Therapeutics Inc Inc. (HRTX) Price Performance: The Role of Supply and Demand - The InvestChronicle
Can you now get a good deal on Heron Therapeutics Inc’s shares? - US Post News
Squarepoint Ops LLC Purchases 286,160 Shares of Heron Therapeutics, Inc. (NASDAQ:HRTX) - MarketBeat
Buying Buzz: Heron Therapeutics Inc [HRTX] EVP, Chief Development Officer Forbes William P purchases 25,000 shares of the company – Knox Daily - Knox Daily
HRTX’s Stock Market Pendulum: Swinging Between Gains and Losses - The InvestChronicle
When Can We Expect A Profit From Heron Therapeutics, Inc. (NASDAQ:HRTX)? - Simply Wall St
Get in on Heron Therapeutics Inc’s (HRTX) buy-in window today! - SETE News
Heron Therapeutics, Inc.'s (NASDAQ:HRTX) Path To Profitability - Yahoo Finance
Heron Therapeutics, Inc. (NASDAQ:HRTX) Shares Acquired by Marshall Wace LLP - Defense World
Heron Therapeutics Inc’s results are impressive - US Post News
Marshall Wace LLP Boosts Holdings in Heron Therapeutics, Inc. (NASDAQ:HRTX) - MarketBeat
Market Momentum Report: Heron Therapeutics Inc (HRTX)’s Negative Close at 1.99 - The Dwinnex
Clearline Capital LP Sells 1,280,938 Shares of Heron Therapeutics, Inc. (NASDAQ:HRTX) - MarketBeat
Heron gains on FDA nod for new Zynrelef application - MSN
Renaissance Technologies LLC Reduces Position in Heron Therapeutics, Inc. (NASDAQ:HRTX) - Defense World
Heron Therapeutics Inc [NASDAQ: HRTX] Sees Decrease in Stock Value - Knox Daily
Renaissance Technologies LLC Lowers Stock Position in Heron Therapeutics, Inc. (NASDAQ:HRTX) - MarketBeat
Heron Therapeutics’ (HRTX) Buy Rating Reiterated at Needham & Company LLC - Defense World
Needham & Company LLC Reaffirms "Buy" Rating for Heron Therapeutics (NASDAQ:HRTX) - MarketBeat
Adversity is less terrifying than hope: Heron Therapeutics Inc (HRTX) - SETE News
Heron stock gains on FDA nod for Zynrelef method (NASDAQ:HRTX) - Seeking Alpha
Heron Therapeutics Announces FDA Approval of the Prior Approval Supplement Application for ZYNRELEF® Vial Access Needle ("VAN") - PR Newswire
Heron Therapeutics, Inc. (NASDAQ:HRTX) Shares Bought by Rhumbline Advisers - Defense World
Heron Therapeutics Inc (HRTX) stock on the rise: An overview - US Post News
Wealth Alliance Has $112,000 Stake in Heron Therapeutics, Inc. (NASDAQ:HRTX) - Defense World
Acadian Asset Management LLC Makes New Investment in Heron Therapeutics, Inc. (NASDAQ:HRTX) - Defense World
E Fund Management Co. Ltd. Acquires New Shares in Heron Therapeutics, Inc. (NASDAQ:HRTX) - Defense World
Heron Therapeutics, Inc. (NASDAQ:HRTX) Shares Sold by Orchard Capital Management LLC - Defense World
Bank of New York Mellon Corp Purchases 113,655 Shares of Heron Therapeutics, Inc. (NASDAQ:HRTX) - Defense World
Pekin Hardy Strauss Inc. Has $88,000 Stake in Heron Therapeutics, Inc. (NASDAQ:HRTX) - Defense World
Heron Therapeutics, Inc. (NASDAQ:HRTX) Shares Purchased by Richmond Brothers Inc. - Defense World
Monitoring Heron Therapeutics Inc (HRTX) after recent insider movements - Knox Daily
Heron Therapeutics, Inc. (NASDAQ:HRTX) Shares Sold by Principal Financial Group Inc. - Defense World
Heron Therapeutics Inc (HRTX) stock: A year of ups and downs - US Post News
Chemotherapy Induced Nausea and Vomiting Treatment Market is Set to Reach US$ 12,688.0 Million by 2034 | Fact.MR - GlobeNewswire Inc.
Holdings of Heron Therapeutics Inc (HRTX) are aligned with the stars - SETE News
Market Highlights: Heron Therapeutics Inc (HRTX) Ends on a High Note at 1.87 - The Dwinnex
Headlands Technologies LLC Acquires 79,609 Shares of Heron Therapeutics, Inc. (NASDAQ:HRTX) - Defense World
Heron Therapeutics, Inc. (NASDAQ:HRTX) Shares Sold by Los Angeles Capital Management LLC - Defense World
The time has not yet come to remove your chips from the table: Heron Therapeutics Inc (HRTX) - SETE News
Heron Therapeutics: Zynrelef Developments Are Unlikely To Provide Relief To Investors - Seeking Alpha
Heron Therapeutics Announces Appointment of Brett Fleshman as Chief Business Officer - Kilgore News Herald
How should investors view Heron Therapeutics Inc (HRTX)? - US Post News
Heron Therapeutics, Inc. (NASDAQ:HRTX) Shares Sold by Monaco Asset Management SAM - MarketBeat
Market Recap: Heron Therapeutics Inc (HRTX)’s financial ratios: A comprehensive overview - The Dwinnex
Heron Therapeutics announces second-quarter financial results - Healio
5.11%
0.50%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Capitalizzazione:
|
Volume (24 ore):